---
document_datetime: 2025-01-29 16:44:04
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/irbesartan-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: irbesartan-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6118993
conversion_datetime: 2025-12-30 00:26:07.897786
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Irbesartan Zentiva

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | C.I HUMAN AND VETERINARY MEDICINAL | 29/01/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000247281                     | PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                           |            |     |    |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Variation type IB / EMA/VR/0000238892 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                | 18/12/2024 | N/A |    |
| Variation type IA / EMA/VR/0000231422 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted | 27/10/2024 | N/A |    |
| Article 61(3) / EMA/N/0000231612      | - Notification acc. Article 61(3) - Update of the package leaflet with revised contact details of local representatives and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD                                                                                           | 14/10/2024 |     | PL |

<div style=\"page-break-after: always\"></div>

| template v10.4.   |
|-------------------|